Juno Therapeutics, Inc. (NASDAQ:JUNO) Given Average Rating of “Hold” by Brokerages
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) have earned a consensus rating of “Hold” from the sixteen research firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $30.93.
A number of research analysts have recently commented on the stock. Vetr raised shares of Juno Therapeutics to a “buy” rating in a report on Tuesday, May 23rd. Zacks Investment Research cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Wedbush reissued a “neutral” rating and issued a $24.00 target price on shares of Juno Therapeutics in a report on Tuesday, June 6th. BidaskClub raised shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Finally, BTIG Research cut shares of Juno Therapeutics from a “neutral” rating to a “sell” rating and increased their target price for the stock from $12.00 to $23.00 in a report on Tuesday, June 6th.
In other news, Director Anthony B. Evnin bought 9,000 shares of the firm’s stock in a transaction on Tuesday, June 20th. The stock was acquired at an average price of $24.40 per share, with a total value of $219,600.00. Following the transaction, the director now owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Insiders sold 8,053,500 shares of company stock valued at $217,594,440 in the last ninety days. 15.26% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank increased its stake in Juno Therapeutics by 19.0% in the second quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 1,741 shares in the last quarter. BlackRock Inc. increased its stake in Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after buying an additional 110,503 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in Juno Therapeutics by 9.0% in the second quarter. TIAA CREF Investment Management LLC now owns 188,481 shares of the biopharmaceutical company’s stock worth $5,634,000 after buying an additional 15,491 shares in the last quarter. Teachers Advisors LLC increased its stake in Juno Therapeutics by 15.4% in the second quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after buying an additional 9,890 shares in the last quarter. Finally, Leisure Capital Management purchased a new stake in Juno Therapeutics during the second quarter worth $255,000. 64.60% of the stock is owned by institutional investors and hedge funds.
Shares of Juno Therapeutics (NASDAQ:JUNO) opened at 27.97 on Friday. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $35.04. The firm’s market cap is $2.93 billion. The firm has a 50-day moving average of $29.03 and a 200 day moving average of $24.53.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. The company had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm’s revenue was down 22.8% compared to the same quarter last year. During the same period last year, the company posted ($0.64) EPS. On average, equities analysts predict that Juno Therapeutics will post ($3.13) earnings per share for the current year.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.